Compare UMC & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UMC | KVUE |
|---|---|---|
| Founded | 1980 | 2022 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Specialty Chemicals |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3B | 33.7B |
| IPO Year | 1997 | 2023 |
| Metric | UMC | KVUE |
|---|---|---|
| Price | $13.03 | $17.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $19.45 |
| AVG Volume (30 Days) | 10.9M | ★ 14.9M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | 2.92% | ★ 4.82% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | N/A | ★ 0.76 |
| Revenue | N/A | ★ $15,124,000,000.00 |
| Revenue This Year | $11.22 | $4.85 |
| Revenue Next Year | $10.15 | $2.63 |
| P/E Ratio | ★ $18.95 | $23.13 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.56 | $14.02 |
| 52 Week High | $13.39 | $25.17 |
| Indicator | UMC | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 70.20 | 49.66 |
| Support Level | $6.86 | $17.20 |
| Resistance Level | N/A | $17.74 |
| Average True Range (ATR) | 0.40 | 0.31 |
| MACD | 0.17 | 0.03 |
| Stochastic Oscillator | 90.83 | 51.92 |
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 5% market share in 2024 after TSMC and SMIC. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the US, and South Korea. UMC features a diverse customer base that includes Texas Instruments, MediaTek, Intel, Broadcom, Novatek, and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 19,000 people as of February 2025.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.